• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AXSM

    Axsome Therapeutics Inc.

    Subscribe to $AXSM
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: axsome.com

    Peers

    $BTAI
    $CAPR
    $FMTX
    $ODT
    $RLAY
    $TXMD
    $TNYA

    Recent Analyst Ratings for Axsome Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    9/3/2024$140.00Overweight
    Wells Fargo
    8/6/2024$95.00 → $106.00Neutral → Buy
    BofA Securities
    7/22/2024$130.00Buy
    Needham
    4/29/2024$90.00 → $115.00Equal-Weight → Overweight
    Morgan Stanley
    3/19/2024$108.00Outperform
    Robert W. Baird
    2/6/2024$111.00Buy
    UBS
    1/25/2024$126.00Outperform
    RBC Capital Mkts
    See more ratings

    Axsome Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Axsome Therapeutics Inc.

      10-Q - Axsome Therapeutics, Inc. (0001579428) (Filer)

      5/5/25 4:47:38 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      5/5/25 7:33:06 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Axsome Therapeutics Inc.

      DEFA14A - Axsome Therapeutics, Inc. (0001579428) (Filer)

      4/25/25 4:32:39 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Axsome Therapeutics Inc.

      DEF 14A - Axsome Therapeutics, Inc. (0001579428) (Filer)

      4/25/25 4:31:46 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      4/1/25 7:06:48 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      3/25/25 7:06:40 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      3/5/25 7:05:08 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      3/3/25 7:06:01 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Axsome Therapeutics Inc.

      10-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      2/18/25 5:10:58 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      2/18/25 7:06:04 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Axsome Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Axsome Therapeutics with a new price target

      Jefferies initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $200.00

      4/7/25 8:43:21 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Axsome Therapeutics with a new price target

      Deutsche Bank initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $176.00

      2/11/25 7:01:14 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho reiterated coverage on Axsome Therapeutics with a new price target

      Mizuho reiterated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $122.00 from $124.00 previously

      12/31/24 7:54:59 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Axsome Therapeutics with a new price target

      Wells Fargo initiated coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $140.00

      9/3/24 7:42:02 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Axsome Therapeutics from Neutral to Buy and set a new price target of $106.00 from $95.00 previously

      8/6/24 6:19:56 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Axsome Therapeutics with a new price target

      Needham initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $130.00

      7/22/24 7:17:08 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Axsome Therapeutics from Equal-Weight to Overweight and set a new price target of $115.00 from $90.00 previously

      4/29/24 7:19:09 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Axsome Therapeutics with a new price target

      Robert W. Baird initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $108.00

      3/19/24 7:43:22 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Axsome Therapeutics with a new price target

      UBS initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $111.00

      2/6/24 6:22:21 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Axsome Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $126.00

      1/25/24 6:57:41 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Axsome Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      11/28/23 6:51:20 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

      NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

      10/11/23 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Axsome Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 3:46:49 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 7:26:39 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/13/24 4:58:57 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      1/26/24 5:25:22 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Axsome Therapeutics Inc.

      SC 13G - Axsome Therapeutics, Inc. (0001579428) (Subject)

      7/7/23 4:00:22 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/23 5:11:29 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/23 4:06:44 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/23 3:45:32 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Axsome Therapeutics Inc.

      SC 13G - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/23 10:07:26 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/9/23 11:07:47 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Axsome Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

      5/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

      NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month. On May 1, as part of Mental Health America's "Light Up Green" initiative, Axsome's New York City headquarters, the One World Trade Center building, will be lit in green, the color for mental health awareness, and through the building's Spireworks program. "Mental Health America's 2024 data co

      5/1/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Participate in Upcoming Investor Conferences

      NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming investor conferences in May: The Citizens 2025 Life Sciences ConferenceThe Company will present on Wednesday, May 7, 2025, at 1:30 p.m. ET in New York, NY BofA Securities 2025 Health Care ConferenceThe Company will present on Tuesday, May 13, 2025, at 3:00 p.m. PT in Las Vegas, NV 2025 RBC Capital Markets Global Healthcare ConferenceThe Company will present on Tuesday, May 20, 2025, at 3:05 p.m. ET in New York, NY Mizuho Neu

      4/22/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentation

      4/8/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

      Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation Presentation featuring network meta-analysis of SYMBRAVO® versus oral CGRPs NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California. Oral and poster presentations include data from the positive pivo

      4/4/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

      Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS). In the overall patient population, the study did not demonstrate a statistically significant change on the Montgomery-Åsberg Depression Ra

      4/1/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

      Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol) Statistically significant reduction in overall ADHD disease severity as measured by the CGI-S score compared to placebo (p=0.017, key secondary endpoint, 150 mg solriamfetol) Statistically significant rate of clinical response on the AISRS compared to placebo (p=0.024, 150 mg solriamfetol) Onset of action as early as Week 1 compared to placebo (p=0.036, AISRS, 150 mg solriamfetol) Well tolerated with safety profile generally consistent with prior solriamfetol trials NEW YORK, March 25, 2025 (GLOBE

      3/25/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

      NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. (Hikma) resolving patent litigation related to Axsome's product Sunosi® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hikma of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Under the ter

      3/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting a supplemental NDA (sNDA) submission for AXS-05 in Alzheimer's disease agitation. AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor. The purpose of the meeting was to reach agreement with the FDA on the proposed content and format of the Company's planned sND

      3/3/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Participate in Upcoming Investor Conferences

      TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferenceThe Company will present on Tuesday, March 4, 2025, at 9:50 a.m. ET in Boston, MA Leerink Partners Global Biopharma ConferenceThe Company will present on Wednesday, March 12, 2025, at 10:40 a.m. ET in Miami, FL Live webcasts of the presenta

      2/26/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Axsome Therapeutics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

      Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      8/19/22 12:36:14 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Axsome Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

      5/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentation

      4/8/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity® 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively, representing 89% and 124% year-over-year growth Sunosi® 4Q and full year 2024 net product revenue of $26.2 million and $94.3 million, respectively, representing 16% and 26% year-over-year growth Symbravo® approved in the U.S. for the acute treatment of migraine with or without aura in adults Successful completion of Phase 3 clinical program of AXS-05 in Alzh

      2/18/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

      NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of SYMBRAVO®, a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack. Experience the interactive Multimedia News Release here. During the call, Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine at Dartmouth and Vice President of the New England Institute for Neurology

      1/31/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

      A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours 85% and 77% of patients treated with a single dose of SYMBRAVO did not require migraine rescue medication within 24 hours in two Phase 3 studies SYMBRAVO demonstrated superior efficacy across a broad range of migraine severity (mild, moderate, and severe), and in head-to-head evaluation SYMBRAVO incorporates Axsome's rapid absorption technology and mechanisms that target multiple migraine attack pathways Company to host conference call and webcast Friday, January 31, at 8:00 AM Eastern NEW YORK, Jan. 30, 2025 (GLO

      1/30/25 3:45:00 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

      NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2024 on Tuesday, February 18, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "We

      1/22/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

      ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to placebo (p=0.001, prevention of relapse of Alzheimer's disease agitation) AXS-05 reduced worsening of Alzheimer's disease overall compared to placebo in ACCORD-2 Phase 3 trial (p<0.001, CGI-S Alzheimer's disease overall clinical status) ADVANCE-2 trial did not demonstrate statistical significance on primary endpoint; numerically greater improvements with AXS-05 over placebo (primary and secondary endpoints) Long-term safety trial completed with required number of patients treated for 6 and 12 mo

      12/30/24 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth Second expansion of Auvelity psychiatry sales force planned for 1Q 2025 NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025 Topline results of ADVANCE-2 and ACCORD-2 Phase 3 trials of AXS-05 in Alzheimer's disease agitation on track for 4Q 2024 Topline results of ENCORE Phase 3 trial of AXS-12 in narcolepsy on track for 4Q 2024 Topline results of

      11/12/24 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

      NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts

      10/15/24 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

      Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024 Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024; target enrollment reached Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 2H 2024 SUSTAIN Phase 3 trial of solriamf

      8/5/24 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Axsome Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mahony Susan

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 8:02:19 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Jeffs Roger

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 8:00:39 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Saad Mark E

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 7:59:08 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Maizel Ari

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 7:57:56 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by General Counsel Murdock Hunter R.

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 7:56:12 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Pizzie Nick

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 7:54:49 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Jacobson Mark L.

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 7:53:23 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Tabuteau Herriot

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 7:51:26 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Pizzie Nick exercised 15,000 shares at a strike of $3.50 and sold $1,951,530 worth of shares (15,000 units at $130.10) (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/14/25 9:20:36 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Coleman Mark exercised 9,127 shares at a strike of $9.00, increasing direct ownership by 19% to 57,137 units (SEC Form 4)

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      1/6/25 4:06:29 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care